AbCellera reports Q1 net loss $43.2M; positive Phase 1 data for ABCL635 supports monthly dosing

AbCellera Biologics Inc.

2026-Q1 EPS reported -$0.14 revenue$8,315,000

Net loss of $43.2M ($0.14 loss per share) vs $45.6M loss in Q1 2025; revenue $8.3M up from $4.2M.
Total available liquidity ~$655M ($531M cash + $124M non-dilutive government funding).
ABCL635 Phase 1: favorable tolerability, no liver toxicity; half-life ~24 days supports monthly subcutaneous dosing.
ABCL635 showed sustained dose-dependent suppression of testosterone, a validated NK3R biomarker.
Partner-led programs with downstreams: 40 (down from 44); 14 molecules in clinic unchanged.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AbCellera Biologics Inc. reported first quarter of 2026 results: revenue $8.3 million, net income $43.2 million, EPS $(0.14) per share on a basic and diluted basis.

Period: first quarter of 2026
Revenue: $8.3 million
Net income: $43.2 million
EPS: $(0.14) per share on a basic and diluted basis
Result: reported results

Exact text from the filing

held downstream stakes in 14 molecules in the clinic understood to be progressing on March 31, 2026. Discussion of Q1 2026 Financial Results ● Revenue – Total revenue was $8.3 million, compared to $4.2 million in Q1 2025. ● Research & Development (R&D) Expenses – R&D expenses were $46.7 million, compared to $42.5 million in Q1 2025. ● Sales, General, &

View on SEC.gov

Browse all earnings releases →

AbCellera Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001703057-26-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.